| Literature DB >> 24717448 |
Stephen S Dominy1, Joseph N Brown2, Mark I Ryder3, Marina Gritsenko2, Jon M Jacobs2, Richard D Smith2.
Abstract
The prevalence of HIV-associated neurocognitive disorders (HAND) remains high despite effective antiretroviral therapies. Multiple etiologies have been proposed over the last several years to account for this phenomenon, including the neurotoxic effects of antiretrovirals and co-morbid substance abuse; however, no underlying molecular mechanism has been identified. Emerging evidence in several fields has linked the gut to brain diseases, but the effect of the gut on the brain during HIV infection has not been explored. Saliva is the most accessible gut biofluid, and is therefore of great scientific interest for diagnostic and prognostic purposes. This study presents a longitudinal, liquid chromatography-mass spectrometry-based quantitative proteomics study investigating saliva samples taken from 8 HIV-positive (HIV+), 11 -negative (HIV-) heroin addicts. In addition, saliva samples were investigated from 11 HIV-, non-heroin addicted healthy controls. In the HIV+ group, 58 proteins were identified that show significant correlations with cognitive scores, implicating disruption of protein quality control pathways by HIV. Notably, only one protein from the HIV- heroin addict cohort showed a significant correlation with cognitive scores, and no proteins correlated with cognitive scores in the healthy control group. In addition, the majority of correlated proteins have been shown to be associated with exosomes, allowing us to propose that the salivary glands and/or oral epithelium may modulate brain function during HIV infection through the release of discrete packets of proteins in the form of exosomes.Entities:
Mesh:
Substances:
Year: 2014 PMID: 24717448 PMCID: PMC3981673 DOI: 10.1371/journal.pone.0089366
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Demographics.
| Heroin Dependent, HIV− N = 11 | Heroin Dependent, HIV+ N = 8 | Non-Heroin, HIV− N = 11 | |
| Age (yrs) | 40.00 (2.97) | 42.38 (2.96) | 43.27 (2.97) |
| Weight (kg) | 73.22 (4.48) | 72.16 (3.28) | 78.8 (4.2) |
| Female | 5 [45%] | 0 [0%] | 3 [27.2%] |
|
| |||
| African-American | 1 [9%] | 2 [25%] | 5 [45.4%] |
| White | 7 [64%] | 6 [75%] | 6 [54.5%] |
| Other | 3 [27%] | 0 [0%] | |
|
| |||
| Amphetamines | 7 [64%] | 1 [13%] | 0 [0%] |
| Benzodiazepines | 5 [45%] | 4 [50%] | 0 [0%] |
| Cocaine | 6 [55%] | 7 [88%] | 0 [0%] |
| Marijuana | 7 [64%] | 6 [75%] | 1 [9.0%] |
| Nicotine Use (packs/day) | .83 (.14) | .98 (.25) | 0.07 (0.06) |
| Viral Load | N/A | 9281.25 (8915.30) | N/A |
| CD4 | N/A | 723.75 (221.64) | N/A |
| cART Exposure | N/A | 7 [88%] | N/A |
| Hepatitis C Infection | 10 [91%] | 8 [100%] | 0 [0%] |
Mean (SE).
[ ] percent of sample affected.
p = 0.04.
Figure 1Overview of clinical saliva sample collection and proteomic analysis.
A) Timeline of the three participant cohorts and their respective days of saliva sample collection and DSST testing. The control population was HIV− and heroin independent so no methadone treatment was initiated at day 0. B) Graph of DSST correlation with all identified and quantified saliva proteins from each respective group after sample collection, processing, instrument and data analysis. Proteins shown in red are those which pass the Benjamini-Hochberg corrected P-value of <0.05.
Proteins showing a significant correlation between abundance and DSST score.
| UniProt | Name | Symbol | Corr | P-value |
| P27824 | calnexin | CANX | 0.74 | 9.96E-05 |
| P61158 | ARP3 actin-related protein 3 homolog (yeast) | ACTR3 | 0.62 | 0.00705 |
| Q13885 | tubulin, beta 2A class IIa | TUBB2A | 0.61 | 0.00705 |
| P16152 | carbonyl reductase 1 | CBR1 | 0.6 | 0.00841 |
| P08107 | heat shock 70 kDa protein 1A | HSPA1A | 0.6 | 0.00841 |
| Q13509 | tubulin, beta 3 class III | TUBB3 | 0.59 | 0.00912 |
| P35579 | myosin, heavy chain 9, non-muscle | MYH9 | 0.58 | 0.00912 |
| Q3ZCM7 | tubulin, beta 8 class VIII | TBB8 | 0.58 | 0.00912 |
| O75083 | WD repeat domain 1 | WDR1 | 0.58 | 0.00912 |
| P46940 | IQ motif containing GTPase activating protein 1 | IQGAP1 | 0.57 | 0.00912 |
| Q14134 | tripartite motif containing 29 | TRIM29 | 0.57 | 0.00912 |
| P07437 | tubulin, beta class I | TUBB | 0.57 | 0.00912 |
| Q8TD99 | desmin | DES | 0.56 | 0.00912 |
| A6NNZ2 | tubulin beta-8 chain B | TBB8B | 0.56 | 0.00912 |
| A6NKZ8 | putative tubulin beta chain-like protein | YI016 | 0.56 | 0.00912 |
| P18510 | interleukin 1 receptor antagonist | IL1RA | −0.57 | 0.00912 |
| P21333 | filamin A, alpha | FLNA | 0.56 | 0.00924 |
| Q6PEY2 | tubulin, alpha 3e | TUBA3E | 0.56 | 0.00924 |
| Q96ML2 | vimentin | VIM | 0.55 | 0.00924 |
| Q9H4B7 | tubulin, beta 1 class VI | TUBB1 | 0.54 | 0.0125 |
| P60842 | eukaryotic translation initiation factor 4A1 | EIF4A1 | 0.54 | 0.0128 |
| P63244 | guanine nucleotide binding protein (G protein), beta polypeptide 2-like 1 | GNB2L1 | 0.54 | 0.0133 |
| P11413 | glucose-6-phosphate dehydrogenase | G6PD | 0.53 | 0.0143 |
| P07900 | heat shock protein 90 kDa alpha (cytosolic), class A member 1 | HSP90AA1 | 0.53 | 0.0143 |
| Q9BYX7 | POTE ankyrin domain family, member I | POTEKP | 0.53 | 0.0143 |
| P55072 | valosin containing protein | VCP | 0.53 | 0.0143 |
| P15104 | glutamate-ammonia ligase | GLUL | 0.52 | 0.016 |
| P14780 | matrix metallopeptidase 9 | MMP9 | 0.52 | 0.0162 |
| P59998 | actin related protein 2/3 complex, subunit 4, 20 kDa | ARPC4 | 0.51 | 0.0223 |
| Q71UI9 | H2A histone family, member V | H2AFV | 0.51 | 0.0223 |
| P00491 | purine nucleoside phosphorylase | PNP | 0.5 | 0.0227 |
| O15231 | zinc finger protein 185 (LIM domain) | ZNF185 | 0.5 | 0.0232 |
| P80188 | lipocalin 2 | LCN2 | 0.5 | 0.0271 |
| P62269 | ribosomal protein S18 | RPS18 | 0.49 | 0.0286 |
| P17931 | lectin, galactoside-binding, soluble, 3 | LGALS3 | 0.49 | 0.0291 |
| P35749 | myosin, heavy chain 11, smooth muscle | MYH11 | 0.49 | 0.0291 |
| Q9H882 | myosin-14 | MYH14 | 0.49 | 0.0291 |
| P62244 | ribosomal protein S15a | RPS15A | 0.49 | 0.0303 |
| P35580 | myosin, heavy chain 10, non-muscle | MYH10 | 0.48 | 0.0309 |
| P15153 | ras-related C3 botulinum toxin substrate 2 | RAC2 | 0.48 | 0.031 |
| P26641 | eukaryotic translation elongation factor 1 gamma | EEF1G | 0.48 | 0.0327 |
| P02042 | hemoglobin, delta | HBD | 0.48 | 0.0327 |
| P05164 | myeloperoxidase | MPO | 0.48 | 0.0327 |
| Q6S8J3 | POTE ankyrin domain family, member E | POTEE | 0.48 | 0.0327 |
| O15145 | actin related protein 2/3 complex, subunit 3, 21 kDa | ARPC3 | 0.48 | 0.0332 |
| P02144 | myoglobin | MB | 0.47 | 0.0338 |
| P43490 | nicotinamide phosphoribosyltransferase | NAMPT | 0.47 | 0.0338 |
| P02511 | crystallin, alpha B | CRYAB | 0.47 | 0.0367 |
| A5A3E0 | POTE ankyrin domain family, member F | POTEF | 0.47 | 0.0367 |
| P29401 | transketolase | TKT | 0.47 | 0.0367 |
| P22314 | ubiquitin-like modifier activating enzyme 1 | UBA1 | 0.47 | 0.0367 |
| P30613 | pyruvate kinase, liver and RBC | PKLR | 0.46 | 0.0386 |
| P12814 | actinin, alpha 1 | ACTN1 | 0.46 | 0.0406 |
| P08238 | heat shock protein 90 kDa alpha (cytosolic), class B member 1 | HSP90AB1 | 0.46 | 0.0406 |
| Q549N7 | hemoglobin subunit beta | HBB | 0.45 | 0.0425 |
| P19105 | myosin, light chain 12A, regulatory, non-sarcomeric | MYL12A | 0.45 | 0.0425 |
| Q86Y46 | keratin 73 | KRT73 | 0.45 | 0.0449 |
| P01877 | Ig alpha-2 chain C region | IGHA2 | 0.45 | 0.0467 |
Figure 2Differences in HIV+ vs. HIV− scatter plots of DSST/protein abundance correlation analyses results for four salivary proteins of interest.
(A–D) Scatter plots showing the correlation of specific salivary protein abundance values against measured DSST scores in HIV+, heroin dependent individuals. The proteins include IL1RA (interleukin-1 receptor antagonist), CANX (calnexin), VCP (valosin-containing protein), and UBA1 (ubiquitin-like modifier-activating enzyme 1). All proteins, except for IL1RA, show significant direct correlation of DSST with salivary protein abundance at P-value<0.05. (E–H) Scatter plots showing the same comparison except against HIV− heroin dependent individuals; however, no perceived correlation is observed, i.e., all p-values are well above 0.05. The linear regression is shown by a red line, and the Pearson product-moment correlation score (r) and Benjamini-Hochberg corrected P-values are indicated in the inlay boxes.
Figure 3Inverse relationship of IL1RA ELISA results with DSST scores.
Scatter plot of IL1RA ELISA absolute concentrations (circles and dotted lines) and DSST scores (triangles and solid lines) over time across 6 HIV-positive individuals showing consistent inverse correlation. Sampling time points include 1 (the day participant presents to the methadone clinic and begins first dose), 2 and 3 (second and third sessions ∼35 and 36 days of methadone, respectively), and 4 (∼100 days on methadone). The Pearson product-moment correlation scores are shown in the lower left corner of each scatter plot.
Figure 4Overview of differentially abundant saliva proteins across methadone treatment.
A) and B) Heat map of all differential protein abundances in the HIV+ and HIV−, heroin dependent cohorts respectively due to methadone treatment (see supplemental table 3 for complete list) at p value <0.05. Clustering is based upon a Pearson distance metric with K-means clustering (K:5). Protein abundance values were scaled for plotting. C) Venn diagram showing the overlap between the respective HIV +/− heat map results and the previous 58 DSST correlating saliva proteins.
Figure 5A graphical representation of the overlap between 47 salivary proteins that demonstrated significant positive correlations with DSST scores in HIV+ heroin addicts and exosomal proteins identified in the ExoCarta database [73].
Proteins are grouped by functional categories for visualization purposes, and not sub-exosomal localization. Adapted from Mathivanin et al. [105].